ClinicalTrials.Veeva

Menu

Gabapentin in Patients at Clinical Risk for Psychosis

N

New York State Psychiatric Institute

Status and phase

Terminated
Phase 2
Phase 1

Conditions

Clinical High Risk for Psychosis

Treatments

Drug: Gabapentin
Drug: Placebo

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The purpose of this study is to test the effects of the drug gabapentin on brain function thought to be important in the development of schizophrenia. Researchers think that treating a brain region with gabapentin (the hippocampus) may reduce the risk for developing schizophrenia.

Full description

Six week, single site, proof-of concept, randomized double-blind placebo-controlled pilot study to examine the effects of moderate dose gabapentin (3600mg) in n= 100 putatively prodromal patients on hippocampal activity.

Enrollment

9 patients

Sex

All

Ages

18 to 30 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. COPE patient between age of 18-30
  2. Capacity to give informed consent
  3. Currently using a reliable method of birth control (female) (condom plus spermicide, diaphragm plus spermicide, IUD, birth control pills, norplant, vasectomy in partner)

Exclusion criteria

  1. Metal implants in body or a history of metal working, or more than one past MRI scan with gadolinium
  2. Lifetime diagnosis of asthmatic symptoms within the past 3 years or known sensitivity to contrast agents
  3. Lifetime diagnosis of renal failure/disease
  4. Acute neurological, neuroendocrine,or medical disorder including renal insufficiency
  5. Lifetime diagnosis of hypertension or diabetes
  6. Intelligence Quotient (IQ) < 70
  7. Acute risk for suicide and/or violence
  8. Pregnant, lactating
  9. Current abuse of substances (alcohol, cocaine, stimulants, cannabis, opiates, sedative hypnotics)
  10. Current use or anticipated need for antipsychotics or mood stabilizers (all antipsychotics, also Depakote, lithium, lamotrigine, pregabalin or any med with a mechanism of action like gabapentin)
  11. The Clinical Global Impressions Scale (CGI)-improvement score during study equal to or greater than 6

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

9 participants in 2 patient groups, including a placebo group

Gabapentin
Experimental group
Description:
Gabapentin 3600mg PO daily
Treatment:
Drug: Gabapentin
Placebo
Placebo Comparator group
Description:
Matching placebo PO daily
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems